Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data In Crohn's Disease To Be Featured In Oral Presentation At 2009 Digestive Disease Week
ChemoCentryx, Inc., announced that data from the company"s PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn"s disease Trial) Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn"s disease will be presented in an oral session at the upcoming 2009 Digestive Disease Week (DDW) meeting. Traficet-EN is an orally-available small molecule drug that controls the inappropriate immune system response underlying inflammatory bowel diseases by blocking the CCR9 chemokine receptor. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn"s disease and other inflammatory disorders of the gastrointestinal system. DDW 2009 will be held on May 30 - June 4, 2009, at McCormick Place in Chicago, Illinois.

Swiss Initiative In Systems Biology Launches New Projects
In the second call for proposals, projects focus on either the development of new technologies or on the interface between biomedical research and genomics. The Swiss National Science Foundation (SNSF) approved six RTD-projects today. They will engage a total of 47 research groups from both Swiss Federal Institutes of Technology (ETH Zurich und EPF Lausanne), as well as from the Universities of Basel, Lausanne, Geneva and Zurich. The Friedrich-Miescher Institute of the Novartis Research Foundation is also represented as the only privately financed institution. Eight groups belong simultaneously to one of the above-mentioned universities and to the Swiss Institute for Bioinformatics.
News of the day
Brain Irradiation In Lung Cancer
A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer reduced the risk of metastases to the brain within the first year after treatment. The study was presented at the American Society of Clinical Oncology annual meeting in Orlando, June 1.
Public Health

World's Biggest Cardiology Meeting, ESC Congress 2009 To Be Held In Barcelona

The European Society of Cardiology Congress 2009, the world"s biggest international meeting in Cardiology will be held in Barcelona, Spain, from 29 August to 2 September. The meeting, which is expected to attract over 30,000 delegates, will provide opportunities for education, hearing about the latest ground breaking research and gaining deeper insights into the most recent developments and innovations in the diagnosis, treatment and prevention of Cardiovascular Disease. Delegates will include clinicians, basic scientists, epidemiologists, nurses, technicians and key opinion leaders in the field. The latest results will be presented in the Hotline and Clinical trials sessions, with unique opportunities for delegates to have face to face interactions with the investigators. In addition, over 4,000 abstracts, featuring original research, will be show cased at the meeting. The educational aspects of the congress include the "Meet and Read with the Experts" sessions and the highly acclaimed FOCUS Sessions with live transmissions and practical take home messages, not to mention reports on the latest ESC guidelines. Prevention and risk factor identification is the special theme of this year"s meeting, giving an opportunity for doctors, scientists, governments and the general public to come together to discuss ways of decreasing the burden of cardiovascular disease on society. Altogether there are 50 separate sessions on prevention in the pre arranged programme, and a special abstract session focusing on prevention research. Additional highlights of this year"s meeting include new joint sessions with sister societies, such as the European Society of Medical Oncology, looking at issues such as the cardiovascular effects of oncology drugs, a full day on Congenital Heart Disease and a new joint session with the European Commission exploring the issues around how the European Commission supports cardiovascular Research. A strong component is dedicated to basic science, including a hotline session looking at the latest development, a translational bench to bedside track and a special abstract session. For the first time ESC 2009 will offer the opportunity for delegates to gain hands-on image and device education from clinical experts. The sessions, which are being held in purpose-built classrooms, have been organised by our industry partners, will be available free on a first come, first served basis. There will also be over 80 satellite symposia and workshops featuring the latest innovations in pharma and equipment. All this is set against the truly inspirational city of Barcelona, with is magnificent Gaudi architecture, superb cuisine and world famous football team. "ESC 2009 promises to be a true festival of cardiology. There will be opportunities for hearing about the latest ground breaking trials, continuing education, not to forget the unrivalled opportunity for networking with colleagues from all disciplines of cardiology and finding out about practices in different countries," says Professor Fausto Pinto, Chairperson of the Congress Programme committee. ESC Press Office European Society of Cardiology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009